The Annals of pharmacotherapy · 2022
Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Long Allissa, Salvo Marissa
Аннотация
OBJECTIVE: To describe the pharmacology, clinical and safety evidence, and relevance to clinical practice of finerenone.
DATA SOURCES: A literature search was conducted utilizing PubMed, MEDLINE, and clinicaltrials.gov with search terms of "finerenone" and "BAY94-8862."
STUDY SELECTION AND DATA EXTRACTION: All available studies with human participants in English were considered. Studies were included if they investigated drug pharmacology, efficacy, and safety information.
DATA SYNTHESIS: In addition to standard of care with a renin-angiotensin system inhibitor (RASi), finerenone lowered the risk of kidney disease progression (17.8% vs 21.1%) in patients with type 2 diabetes mellitus and chronic kidney disease compared to placebo. Similarly, finerenone reduced cardiovascular risk in patients with type 2 diabetes mellitus and chronic kidney disease compared to placebo (12.4% vs 14.2%).
RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: It is anticipated that finerenone will be added to therapy after a RASi and a sodium-glucose cotransporter-2 inhibitor, as tolerated, based on adverse events and potassium levels.
CONCLUSIONS: Finerenone offers a unique approach to further delay the progression of chronic kidney disease in patients with type 2 diabetes mellitus. It also provides another option for patients who cannot tolerate RASi or sodium-glucose cotransporter-2 inhibitors.
DATA SOURCES: A literature search was conducted utilizing PubMed, MEDLINE, and clinicaltrials.gov with search terms of "finerenone" and "BAY94-8862."
STUDY SELECTION AND DATA EXTRACTION: All available studies with human participants in English were considered. Studies were included if they investigated drug pharmacology, efficacy, and safety information.
DATA SYNTHESIS: In addition to standard of care with a renin-angiotensin system inhibitor (RASi), finerenone lowered the risk of kidney disease progression (17.8% vs 21.1%) in patients with type 2 diabetes mellitus and chronic kidney disease compared to placebo. Similarly, finerenone reduced cardiovascular risk in patients with type 2 diabetes mellitus and chronic kidney disease compared to placebo (12.4% vs 14.2%).
RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: It is anticipated that finerenone will be added to therapy after a RASi and a sodium-glucose cotransporter-2 inhibitor, as tolerated, based on adverse events and potassium levels.
CONCLUSIONS: Finerenone offers a unique approach to further delay the progression of chronic kidney disease in patients with type 2 diabetes mellitus. It also provides another option for patients who cannot tolerate RASi or sodium-glucose cotransporter-2 inhibitors.